Introduction
Flaviviruses are small, spherical, enveloped viruses that consist of two envelope associated proteins, E and prM (precursor to M), and a nucleocapsid that comprises the core protein (C) in association with approximately 11 kb of single strand, positive sense RNA (reviewed in Chambers et at., 1990) . Genomic RNA provides the only message and represents one long open reading frame containing three structural and seven non-structural genes in the order 5' C-prM/M-E-NS1-NS2A-NS2B-NS3-NS4A-NS4B-NS5 3'. Translation of the coding region produces a polyprotein that is co-and posttranslationally cleaved by the viral protease and cell signalase to form individual viral proteins.
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antibodies to the E protein provide solid protection to mice against homologous flavivirus challenge (Gould et al., 1986; Kimura-Kuroda & Yasui, 1988; Hawkes et aL, 1988) , while antibodies to the NS1 protein protect to a lesser extent apparently through complement-mediated lysis or antibody-dependent cell-mediated cytotoxicity (ADCC) (Schlesinger et al., 1990 (Schlesinger et al., , 1993 Jacobs et al., 1994) . In vitro studies have shown that the flavivirus NS3 protein contains immunodominant cytotoxic T (Tc) cell determinants for several major histocompatibility complex (MHC) class I restricted elements (Kurane et al., 1989 (Kurane et al., , 1991 Parrish et al., 1991; Rothman et al., 1993; Lobigs et al., 1994) .
The role of these humoral and cellular immune responses in protection against flavivirus-induced disease has been difficult to demonstrate in vivo with most flaviviruses due to the lack of a good animal model. The common laboratory strains of mice are only fully susceptible to flavivirus infection by peripheral routes of inoculation in the first few weeks of life (Grossberg & Scherer, 1966; Boyle, 1979) . As mice mature they become more resistant to flavivirus infection by this route of inoculation, even when using high doses of virus, probably due to maturation of the immune system, lack of virus replication at the inoculation site and tightening of the cell junctions in the blood-brain barrier. Although some strains of Japanese encephalitis virus (JE) ( 
Methods
Virus stocks. MVE strain F/3/51 was used to infect Vero cells (m.o.i. = 1) and virus stocks were prepared as clarified culture medium collected at 72 h post-infection.
Cell cultures. 143B, SW13, L929 and CV1 cells were grown in RPMI 1640 supplemented with L-glutamine, antibiotics and 10% FBS at 37 °C in a 5 % CO 2 atmosphere. Vero and C6/36 cells were cultured in M199 medium (Gibco), and similarly supplemented for growth and incubated at 28 °C in 5% CO 2 (C6/36) or 37 °C with 15 mM-HEPES (Vero).
Monoclonal antibodies. MAbs to the prM, E and NS1 proteins of MVE virus have been described previously (Hall et al., 1988 (Hall et al., , 1990 .
Construction of recombination plasmids. The vaccinia virus recombination plasmid pVPGJ4 was kindly provided by Denis Trent, CDC, Fort Collins, Co., USA. This vector was derived from pGS62 by deleting BamHI and Sinai sites in order to regenerate the original p7.5 promoter sequence (Esposito et al., 1987) . A cDNA fragment corresponding to 70 nucleotides at the 3' end of the E gene, all of the NS 1 and NS2A genes and 70 nucleotides at the 5' end of the NS2B gene of MVE virus was generated by PCR using Taq polymerase (Biotech). Primers 2411s (TG AAT TCA ATT GCT GCT TTC C) and 4295 (GGAATTC A ATC AAT GTC TAG CTC A), incorporating MVE sequence (underlined), and EcoRI sites (italicized), were used to amplify cDNA corresponding to nucleotides 24114295 of the MVE genome from the plasmid 2/1/22 (Dalgarno et al., 1986) . The PCR product was cloned into the pCR II TA cloning vector (Invitrogen) and the EeoRI fragment excised and cloned into EcoRI-digested pVPGJ4 to produce pVPNS1 so that the ATG, immediately preceding the EcoRI cleavage site, served as the initiation codon.
Production of recombinant VV. The methods described by Mackett et al. (1984) , with some modifications, were used to transfect wild-type VV-infected Vero cells with pVPNS1 and to isolate thymidine kinaseminus recombinant viruses. Recombinants that were positive for the NS1 gene by hybridization were plaque purified and tested for expression of NS1 by immunofluorescence using NS1 specific MAbs. VV virus recombinants expressing NS1 (VV-NS1) were cultured in CV1 cells by inoculation at an m.o.i, of 5 and cultured for 48 h. Infected cells were then scraped into medium and freeze-thawed three times to release virus; the virus suspensions were then homogenized by repeated aspiration through a Pasteur pipette. Virus titres were determined by plaque assay on CVI cells. Other vaccinia virus recombinants expressing MVE virus proteins, VV-AC (prM-E-NS1-NS2A) and VV-STR (C-prM-E-NS1-NS2A), have been described previously (Lobigs, 1993) .
Analysis of MVE virus proteins expressed by VV recombinants.
Recombinant viruses VV-STR, VV-AC and VV-NS1 were cultured in CV1 cells (m.o.i. = 5) for 48 h and infected cells pelleted and resuspended in lysing buffer (2 % Triton X-100, 1% NP40, 1% sodium deoxycholate, 0.1% SDS in PBS pH 7.4) overnight at 4 °C. Lysates were then clarified, the recombinant protein separated by PAGE and analysed by Western blot with a cocktail of anti-NS 1 MAbs (Hall et al., 1990) . Recombinant antigens were also analysed by ELISA. VV-WT, VV-STR, VV-AC and VV-NS1 were cultured in CV1 cells in 96-well trays. At 48 h after infection, cell monolayers were rinsed with PBS, fixed with 20 % acetone in PBS for 1 h at 4 °C then dried at 37 °C overnight. Twofold dilutions of MAbs to the prM, E or NS1 proteins of MVE virus were then incubated on fixed monolayers for 1 h at room temperature. After washing, bound MAb was detected using goat antimouse conjugated horse-radish peroxidase (Bio-Rad) followed by incubation with the chromogenic substrate ABTS.
Purification ofNS1. Native, dimeric NS 1 was immunoaffinity purified from 50 h MVE virus-infected Vero culture supernatant using a previously described method (Hall et al., 1991) . Purity of protein was tested by ELISA using anti-E and anti-NS1 MAbs and by visualizing the protein on 10 % SDS-PAGE gels after silver staining (Wray et al., 1981) .
Immunization of mice. Specific pathogen free male (BALB/c x C3H/RV) F 1 hybrid mice were immunized with approximately 5 gg of pure NS1 protein with 50 % Freund's complete adjuvant in PBS by the i.p. route at 34 weeks of age. A second dose of 5 gg was administered i.p. with incomplete Freund's adjuvant at 5 6 weeks of age, and the final boost consisted of 5 gg of protein injected intravenously without adjuvant at 8-10 weeks of age. Control mice were inoculated at these times with 5 gg of BSA using the same dose of adjuvant, or sublethally infected with 1000 TCID~0 of MVE virus by the i.p. route concurrent with the second dose of NS1. In VV experiments hybrid mice were immunized by i.p. injection with 107 p.f.u, of wild-type or recombinant VV at 5 6 weeks of age. This was repeated 3 weeks later. Two weeks after the final immunization all mice were bled for serology or adoptive transfer. Two days later animals were challenged with 1000 TCIDs0 of MVE virus in 5 ~1 by the i.c. route and monitored for signs of encephalitis for 21 days,
Depletion o f C D 8 + T cells.
At 5 and 2 days prior to virus challenge mice were injected i.p. with a dose of anti-Lyt-2 antibody YTS 169.4 (Cobbold et al., 1984) sufficient to deplete CD8 + T cells, Depletion was confirmed on the day of challenge and at 10 days post-infection by FACscan analysis of ftuorescently labelled CDS+ splenic lymphocytes.
Adoptive transfer. Serum (250 gl) was transferred i.p. to susceptible 18 20-day-old male BALB/c or 10-week-old F 1 hybrid male recipients 2 h prior to an i.p. (BALB/c) or i.c. (F1 hybrid) challenge with 1000 TCIDs0 of MVE virus. At 12-16 h after challenge a further 250 gl of serum was transferred i.p. and mice were observed for 21 days.
Serology. Doubling dilutions of prechallenge sera from immunized mice were tested for antibody to MVE viral proteins by ELISA on acetone-fixed infected cells (Hall et al., 1990) or on virus adsorbed to the solid phase (Hall et al., 1991) . The highest dilution to give an absorbance of ~> 0.1, and at least twice that produced by the same dilution on control antigen, was taken as the end point.
Western blot procedures have previously been described in detail (Hall et al., 1990) . MVE viral proteins in lysates of infected C6/36 cells were resolved by SDS-PAGE, electroblotted onto membranes and immunostained with mouse antiserum.
In the plaque reduction neutralization test (PRNT), 5(~100 p.f.u, of MVE virus was incubated with doubling dilutions of sera for 1 h at 37 °C before inoculation onto Vero cell monolayers in 1-5 cm diameter culture wells. Inoculum was removed after 1 h and cells overlaid with MEM containing 2 % FBS and 1.75 % methyl cellulose. After 6 days incubation at 37 °C with 5 % CO2, monolayers were fixed and stained, and plaques counted. Serum dilutions that reduced the number of plaques by 70 % compared with that in control wells were taken as the end point.
For complement-mediated cytolytic (CMC) assays, monolayers of SW 13, L929, Vero and C6/36 cells were infected with a sufficiently high m.o.i, of MVE virus to produce 100% infection as determined by immunofluorescence at 24 h post-infection. Cells were trypsinized for 10 rain then resuspended, washed in serum-free RPMI, and 107 cells were labelled with 1 mCi of 5~Cr (sodium chromate) in a volume of 200 lal for 30 min at 37 °C. Labelled cells were then washed in RPMI, and 105 cells in 25 lal were added to each well of a 96-well plate and incubated with 25 gl of serum dilutions (1/5 and 1/50) on ice for 15 rain. Twenty-five pl of guinea-pig complement (CSL, Melbourne, Australia) diluted in RPMI was added to test wells and plates were incubated at 37 °C for 45 rain. Complement-mediated lysis of a similar number of BALB/c thymic cells in the presence of anti-Thy-1 antibody 30H12 (ATCC TIB 107) was used as the positive control and to determine the optimum dilution of complement. Culture medium from each well was then harvested and analysed for radioactivity on a gamma counter (Packard). Percent lysis was calculated by the formula:
where test is the c.p.m, of test supernatant, SR is spontaneous release by labelled cells that received no serum or complement, and TR is total release by labelled cells lysed by 1% Triton X-100.
Results

Analysis of purified NS] and recombinant VV expressed M V E viral proteins
Purified NS1 was analysed by protein specific MAbs in ELISA and Western blot, and by silver stain of the preparation resolved on SDS-PAGE. NS1, pre- dominantly in dimer form, was the only protein detected (Fig. 1) . NS1 protein expressed by VV-NS1, VV-STR and VV-AC cultured in CV1 cells was compared to native viral protein produced in MVE virus infected cells by Western blot using a cocktail of anti-NS1 MAbs. This revealed that VV-AC, VV-NS1 and VV-STR expressed dimeric NS1 that co-migrated with authentic NS1 produced in MVE-infected cells (Fig. 2) . ELISA analysis revealed that all MAbs produced to the native NS1 protein of MVE virus reacted equally well with cells infected with VV-NS1, VV-STR and VV-AC antigens (Table 1 ). All anti-E MAbs reacted with cells infected with VV-STR or VV-AC, but failed to react with VV-NS1 infected cells. Two anti-prM MAbs (M-Bll and M2-1E7) bound strongly to VV-AC infected cells but failed to react with cells infected with VV-STR and VV-NS1, consistent with the absence of prM in VV-NS1 or greatly reduced cleavage of C-prM in VV-STR (Lobigs, 1993) .
Susceptibility of resistant, susceptible and F~ hybrid mice to M V E virus challenge
Susceptible, resistant and F 1 hybrid strains were examined for their response to i.c. inoculation with MVE virus. The results, summarized in Table 2 , indicated that BALB/c and (BALB/cxC3H/RV) F 1 hybrid mice showed a similar mortality rate; however, hybrid mice exhibited symptoms of disease 2-3 days later than did BALB/c mice. A similar delay of onset of encephalitis was observed between the susceptible strain C3H/Hej and (C3H/HejxC3H/RV) F1 hybrids (results not shown). C3H/RV mice, on the other hand, were significantly less susceptible. The (BALB/c x C3H/RV) T a b l e 1.
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Reaction of anti-MVE virus MAbs with VV recombinant MVE viral proteins in ELISA
Acetone-fixed infected CVI monolayers were used as antigen in ELISA. A positive reaction was recorded if the absorbance produced by MAb was ~> 0.1 and at least twice that produced on control antigen (uninfected cells). (Table 3) . W e s t e r n blot analysis o f these sera r e v e a l e d (10-14) (9 12) 100 90% (9/10) 9.0+0.3 30% (3/10) 11.0_+0.3 64% (7/11) 12. 6_+0.6 (8-11] (1(~12) (11-16) 10 50% (5/10) 10.0_+0.6 10% (1/10) 12 58% (7/12) 11.3_+0.4 ( 8 13 that the response was specific for NS1. Sera from mice sublethally immunized with live MVE virus or those immunized with VV-AC also produced high levels of antibody which reacted with E and NS1 proteins with equal intensity in Western blot (results not shown). Control mice immunized with BSA or VV-WT produced no antibody reactive to MVE viral proteins.
Vaccinia virus
hybrids were c h o s e n for f u r t h e r studies because B A L B / c mice h a d b e e n used in p r e l i m i n a r y i m m u n iz a t i o n studies w i t h purified NS1.
Protection of hybrid mice against MVE challenge W h e n F 1 h y b r i d m i c e were i m m u n i z e d w i t h p u r e NS1 p r o t e i n a n d c h a l l e n g e d i.c. w i t h M V E virus, m o r t a l i t y ( 1 5 % ) was greatly r e d u c e d c o m p a r e d with c o n t r o l s ( 9 4 % ) a n d time to d e a t h o f n o n s u r v i v o r s p r o l o n g e d (Table 3). H y b r i d mice i m m u n i z e d with r e c o m b i n a n t V V were also p r o t e c t e d . All (10/10) mice i m m u n i z e d w i t h V V -A C ( p r M -E -N S 1 -N S 2 A ) survived, as did 47 % (9/19) o f t h o s e i m m u n i z e d with V V -N S 1 (NS 1 -N S 2 A ) a n d 40 % (4/10) with V V -S T R ( C -p r M -E -N S 1 -N S 2 A ) . O n l y
Analysis of prechallenge sera
M i c e i n o c u l a t e d with p u r e N S 1 , V V -N S 1 o r V V -S T R p r o d u c e d a high titre o f a n t i b o d y to M V E in E L I S A
Prechallenge sera from immunized mice were tested for the ability to neutralize MVE virus, to inhibit haemagglutination (HI) by MVE antigen and to lyse infected cells in the presence of complement (Table 3) . Antibody in antisera reactive to NS1 was unable to neutralize MVE virus nor did it inhibit haemagglutination. In contrast, sera produced to live MVE virus or VV-AC possessed neutralizing and HI activity. All sera produced less than 10% lysis of 24 or 48 h MVE virusinfected L929, Vero, SW13 or C6/36 cells in the presence of complement (Table 1) , which was similar to levels observed with uninfected cells. However, anti-Thy-1 MAb (30H12) induced complement-mediated lysis of 95 100% of BALB/c thymic cells in the same assay (results not shown).
Effect of CD8 depletion
To evaluate whether primary or memory Tc cell mediated immunity contributed to protection of hybrid mice, vaccinated mice were depleted of CD8 ÷ cells prior to virus challenge. After depletion the protection provided by VV-AC was unaffected (Table 4 ). In contrast, the protection provided by VV-NS1 was reduced from 80 % in undepleted to 20% in depleted mice. However, 
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depleted mice succumbed to infection significantly later than unvaccinated controls.
Adoptive transfer of immune serum
When F1 hybrid mice received 0-5 ml of anti-MVE serum, they were solidly protected from a lethal i.c. challenge, while a similar transfer of anti-NS1 serum failed to provide protection (Table 5) . However, the recipients of anti-NS1 serum survived, on average, 48 h longer than mice receiving control serum. Similar results were observed in weanling BALB/c recipients prior to lethal i.p. challenge with MVE virus (Table 5 ).
Discussion
Investigations of the susceptibility of heterozygous resistant [(BALB/cxC3H/RV) F1] and susceptible (BALB/c) mice to i.c. inoculation with MVE virus revealed that F 1 and BALB/c mice showed similar mortality rates (Table 2 ). However, F 1 hybrid mice developed symptoms of encephalitis 2-3 days later than susceptible mice. This was consistent with findings of Sangster et al. (1994) who showed that F 1 mice produce significantly lower virus titres in the brain than BALB/c mice after i.c. inoculation with MVE virus. When F1 hybrid mice were immunized with purified NS1 protein, the majority were protected from i.c. challenge with MVE virus. This is in contrast to the high mortality seen in BALB/c mice that had been immunized and challenged in an identical fashion (results not shown).
Presumably the delay in onset of the disease in F 1 mice and/or the lower virus titres in the brain allowed the NSl-specific immune response to play some protective role. The level of protective immunity generated in mice by vaccination with recombinant VV was also examined in this study. The solid protection induced by VV-AC was apparently mediated by neutralizing antibodies to the E protein although some additional contribution of NS 1 in this construct to protection cannot be excluded. Infection of CV1 cells with this construct results in the secretion of subviral particles that contain prM/M and E embedded in lipid envelope derived from the host cell (Lobigs, 1993) . Similar particles have also been observed in the culture fluid of cells infected with recombinant VV expressing corresponding regions of the JE genome (Mason et al., 1991) . Immunization with these recombinant viruses or purified preparations of the secreted particles has also been shown to protect mice from i.p. challenge with JE virus (Konishi et al., 1992) .
While neutralising antibody is thought to prevent infection of the CNS by virus entering from the peripheral route, infection of the CNS via i.c. inoculation may also require a cytolytic T lymphocyte (CTL) response for virus clearance and protection (Monath, 1986) . When VV-AC vaccinated mice were depleted of CD8 + T cells for up to 10 days post-infection, protection remained complete. This indicates that in the presence of a primed antibody response to the E protein of MVE virus, a CD8 + T cell response is not required for clearance of virus from the CNS. This is consistent with the findings of Levine et al. (1991) who demonstrated that passive transfer of MAbs to the E2 protein of Sindbis virus cleared virus from the neurons of persistently infected SCID mice in the absence of a cellular immune response.
In contrast to VV-AC, VV-STR, which expresses E but does not produce the prM/E heterodimer necessary for secretion (Lobigs, 1993) , did not induce a humoral response to E in mice. However, like VV-NS 1 and AC, this construct expresses NS1 that acquires its native dimeric form and is secreted into the extracellular fluid. This resulted in a strong antibody response to NS1 which apparently provided partial protection in mice vaccinated with VV-STR, VV-NS1 or pure NS1. Prechallenge sera from these mice failed to activate complement-mediated cytolysis of MVE-infected cells, a proposed mechanism of protection induced by antibodies to NS1 of YF virus (Schlesinger et al., 1990) . However, our results are consistent with recent findings by Jacobs et al. (1994) who demonstrated that complementdeficient mice immunized with recombinant adenovirus expressing TBE NS1 were still protected from virus challenge suggesting that another mechanism, such as antibody-dependent cell-mediated cytotoxicity (ADCC), was involved. However, our attempts to demonstate ADCC of MVE-infected L929 cells by BALB/c spleen cells in the presence of sera from these mice were inconclusive (results not shown).
Passive transfer of NS 1-immune sera to recipient mice provided no protection, but delayed the onset of symptoms and death for an average of 48 h. This indicated that primed B or T cells were also required to achieve significant protection. Indeed depletion of CD8 + cells in F 1 hybrid mice vaccinated with VV-NS1 completely ablated protection, indicating a requirement for class I restricted T cells to clear infection. However, findings by Lobigs et al. (1994) that only NS3 contains immunodominant Tc epitopes and that the MVEspecified polyprotein expressed by VV-STR (C-prM-E-NS 1-NS2A) contained no epitopes for Tc cells generated in MVE-infected (CBA) H-2 ~ mice indicates that a cellmediated immunity response is not the primary mechanism of protection in F 1 hybrid mice (H-2~-2 a) immunized with VV-NS 1 or VV-STR. While it is possible that vaccination with recombinants that do not express the dominant NS3 Tc epitopes primes for subdominant The use of F 1 hybrid mice possessing genetic resistance to flavivirus infection proved useful in our studies and overcame the problem of inconsistent mortality rates in adult mice challenged by peripheral routes. Although i.c. inoculation is an unnatural route of entry for the virus, the severity of this form of challenge with a neurotropic virus such as MVE was significantly reduced in these mice due to the lower levels of virus replication in the brain. This has provided a more sensitive animal model to measure the protective response induced by purified viral protein and vaccinia recombinants expressing viral proteins.
